• At least 18 years of age at the time of cemiplimab treatment initiation

• Has been diagnosed with histologically or cytologically documented squamous or non-squamous NSCLC

• Prescribed a cemiplimab-based regimen as part of routine clinical practice as determined by the treating physician per standard of care and in accordance with the Summary of Product Characteristics (SmPC).

• Can understand and complete the study-related questionnaires

• Must be legally capable of providing written consent for participation in the study and have signed informed consent prior to any study activities